Evidence map›Paper›PMID 40296624›Full record

SynthesisCNS & neurological disorders drug targets2025

Valproate Exposure as an

Quezia Damaris Jones Severino Vasconcelos, Michele Aramburu Serafini, Jaqueline Vieira Carletti, Gislei Frota Aragão, Carmem Gottfried, Victorio Bambini-Junior

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in CNS & neurological disorders drug targets, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. GABAFrontiers in pharmacology · 2026
    Review
  2. Current issues in molecular biology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Quezia Damaris Jones Severino VasconcelosDivision of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Bailrigg, Lancaster LA1 4YE, United Kingdom.ORCID 0000-0003-2128-5749
Michele Aramburu SerafiniDivision of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Bailrigg, Lancaster LA1 4YE, United Kingdom.ORCID 0000-0003-2707-9583
Jaqueline Vieira CarlettiDepartment of Biochemistry, Federal University of Rio Grande do Sul, Rua Ramiro Barcelos, 2600, 90035-003, Porto Alegre, Rio Grande do Sul, Brazil.ORCID 0000-0001-7982-8422
Gislei Frota AragãoSuperior Institute of Biomedical Sciences, Ceará State University, Avenida Dr. Silas Munguba, 1700, 60714-903, Fortaleza, Ceará, Brazil.ORCID 0000-0002-0689-8371
Carmem GottfriedDepartment of Biochemistry, Federal University of Rio Grande do Sul, Rua Ramiro Barcelos, 2600, 90035-003, Porto Alegre, Rio Grande do Sul, Brazil.ORCID 0000-0001-8838-1300
Victorio Bambini-JuniorDivision of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Bailrigg, Lancaster LA1 4YE, United Kingdom.ORCID 0000-0002-8590-6770

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAutism Spectrum Disorder (ASD) is a complex neurodevelopmental disorder with a strong genetic and environmental basis. It frequently causes social and communication deficits, as well as repetitive behaviours. Valproic acid (VPA) has been shown to induce autisticlike features in animal models when administered during critical development periods. However, not much is known about its effect on cells to replicate ASD characteristics in vitro.

objectiveThis review explores in vitro VPA models to elucidate the molecular and morphological characteristics of ASD, emphasizing their potential and proposing directions for future research.

methodsPubMed, SciELO, Embase, Web of Science, and Scopus databases were searched, and 11 studies were included after screening.

resultsThe studies explored VPA's effects on various cell cultures, including human neural cell lines, primary adult neurons, and primary embryonic neurons. VPA was found to be neurotoxic in a dose- and time-dependent manner, with greater toxicity in immature and undifferentiated cells.

conclusionIn vitro models provide valuable insights into the morpho-molecular alterations induced by VPA and their connection to ASD. These findings highlight the need for further research into VPA's cellular effects to deepen our understanding of its role in ASD pathology.

Indexed as

Autism Spectrum DisorderValproic AcidAnimalsHumansNeuronsValproic Acidautism spectrum disorderin vitromorpho-molecular alterations.neuronal cell cultureneurotoxicityValproic acid

Identifiers

PMID40296624

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.